Immunogenicity and adverse reactions of influenza vaccination in elderly patients given acetaminophen or placebo.
Immunogenicity and adverse reactions of influenza vaccination in elderly patients given acetaminophen or placebo.
复制标题
DOI：
10.1016/0928-0197(93)90021-v
复制
发表时间：
1993-07-01
期刊：
影响因子：
--
通讯作者：
Mahony, J
中科院分区：
文献类型：
--
作者：
Chernesky, M;O'Neill, D;Mahony, J
目的是检查老年人群对流感免疫的抗体反应，以及预防性对乙酰氨基酚对含有甲型流感（H3N2 和 H1N1）和 B 抗原的灭活全病毒疫苗引起的不良反应的影响。 1990 年秋季，100 名 65 岁或以上的患者接受了免疫接种，并随机分配接受安慰剂或 1,950 毫克（2 x 975 毫克）对乙酰氨基酚。 They recorded any local and systemic side effects over a 3-day period. Serology was performed on pre- and post (4-6 weeks) -vaccination sera. Age and gender distribution in the study were: 47% who were 75 years or older, and 61% of the patients were female.大多数患者 (97%) 已有甲型或乙型流感抗体。B 山形和 A 台湾 (H1N1) 的平均峰值预免疫抗体滴度为 40，A 上海 (H3N2) 为 80。 Half of each treatment group had a 4-fold or greater rise in antibody titer in response to the vaccine.只有 30% 的患者在前一年接种过疫苗，但 80% 以前从未接种过疫苗的患者表现出对疫苗的 4 倍或更高的血清学反应。然而，接种前后的保护率测量（HI >/= 40）表明，这 3 种病毒的保护率为 81.1-100%，不受治疗、性别或既往疫苗接种史的影响。两个治疗组中出现嗜睡、肌痛、发烧和发冷等全身症状的患者人数同样少，其中约 50% 的患者出现手臂酸痛。尽管约 80% 的先前未接种疫苗的成年人体内的流感疫苗抗原抗体增加了 4 倍，而去年接种疫苗的成年人中只有 30% 出现了加强效应，但免疫后的保护率很高 (81-100%)，并且不受对乙酰氨基酚治疗的影响。 Adverse effects (15% systemic and 50% local) were not ameliorated by 1950 mg of acetaminophen in these elderly patients.
The objective was to examine the antibody responses to influenza immunization in an elderly population and the effect of prophylactic acetaminophen on adverse responses due to inactivated whole virus vaccine containing influenza A (H3N2 and H1N1) and B antigens. During the autumn of 1990, 100 patients 65 years or older were immunized and randomly allocated to receive placebo or 1,950 mg (2 x 975 mg) of acetaminophen. They recorded any local and systemic side effects over a 3-day period. Serology was performed on pre- and post (4-6 weeks) -vaccination sera. Age and gender distribution in the study were: 47% who were 75 years or older, and 61% of the patients were female. Most of the patients (97%) had pre-existing antibodies to Influenza A or B. Average peak preimmunization antibody titers were 40 to B Yamagata and A Taiwan (H1N1) and 80 for A Shanghai (H3N2). Half of each treatment group had a 4-fold or greater rise in antibody titer in response to the vaccine. Only 30% of patients immunized the previous year but 80% of those never vaccinated previously demonstrated a 4-fold or greater serological response to the vaccine. However, measurement of protection rates (HI >/= 40) before and after vaccination indicated 81.1-100% protection for the 3 viruses not influenced by treatment, gender or a history of previous vaccination. Both treatment groups had equally small numbers of patients who recorded systemic symptoms of drowsiness, myalgia, fever and chills and about 50% had arm soreness. Although about 80% of previously unimmunized adults mounted a 4-fold antibody rise to influenza vaccine antigens whereas booster effects were seen in only 30% of those immunized the previous year, protection rates were high (81-100%) after immunization and were not affected by acetaminophen treatment. Adverse effects (15% systemic and 50% local) were not ameliorated by 1950 mg of acetaminophen in these elderly patients.